Immunological concepts and the combination of cyclophosphamide with 5-aza-2'-deoxycytidine on L1210 in vivo.
Experiments were designed to demonstrate the synergism of low dose cyclophosphamide (CY), (15 mg/kg or 45 mg/M2) in combination with 5-aza-2'deoxycytidine (DAC). This dose of CY increased the cytotoxic response to DAC on L1210 tumor in mice by an additional 4 logs of L1210 cell kill or an approximate doubling of the response to DAC alone. These data support the hypothesis that CY at this low dose selectively inhibits suppressor t-cells which normally function to prevent the full cytotoxic potential of DAC from being realized.
D S
DS
Zaharko
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D002470:Cell Survival / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000494:pharmacology; D000077209:Decitabine; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects
D000970:Antineoplastic Agents; D000077209:Decitabine; D003520:Cyclophosphamide; D001374:Azacitidine